Showing 2973 results
-
Press release /
-
Press release /
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority…
-
Press release /Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded…
-
Press release /New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT…
-
Press release /New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral sessionNew ianalumab interim results from Sjögren’s Phase III…
-
Press release /Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent…
-
Press release /First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene,…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous…
-
Press release /Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1Vanrafia reduced protein in urine by 38.3% vs…